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Letrozole therapy alone or in sequence with tamoxifen in women
with breast cancer
Abstract
BACKGROUND: The aromatase inhibitor letrozole, as compared with tamoxifen, improves
disease-free survival among postmenopausal women with receptor-positive early breast cancer. It is
unknown whether sequential treatment with tamoxifen and letrozole is superior to letrozole therapy
alone. METHODS: In this randomized, phase 3, double-blind trial of the treatment of
hormone-receptor-positive breast cancer in postmenopausal women, we randomly assigned women to
receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, or 2 years of treatment
with one agent followed by 3 years of treatment with the other. We compared the sequential treatments
with letrozole monotherapy among 6182 women and also report a protocol-specified updated analysis of
letrozole versus tamoxifen monotherapy in 4922 women. RESULTS: At a median follow-up of 71
months after randomization, disease-free survival was not significantly improved with either sequential
treatment as compared with letrozole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99%
confidence interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 99% CI,
0.76 to 1.21). There were more early relapses among women who were assigned to tamoxifen followed
by letrozole than among those who were assigned to letrozole alone. The updated analysis of
monotherapy showed that there was a nonsignificant difference in overall survival between women
assigned to treatment with letrozole and those assigned to treatment with tamoxifen (hazard ratio for
letrozole, 0.87; 95% CI, 0.75 to 1.02; P=0.08). The rate of adverse events was as expected on the basis
of previous reports of letrozole and tamoxifen therapy. CONCLUSIONS: Among postmenopausal
women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as
compared with letrozole monotherapy, did not improve disease-free survival. The difference in overall
survival with letrozole monotherapy and tamoxifen monotherapy was not statistically significant.
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Background
The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-
free survival among postmenopausal women with receptor-positive early breast can-
cer. It is unknown whether sequential treatment with tamoxifen and letrozole is 
superior to letrozole therapy alone.
Methods
In this randomized, phase 3, double-blind trial of the treatment of hormone-recep-
tor–positive breast cancer in postmenopausal women, we randomly assigned wom-
en to receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, 
or 2 years of treatment with one agent followed by 3 years of treatment with the 
other. We compared the sequential treatments with letrozole monotherapy among 
6182 women and also report a protocol-specified updated analysis of letrozole ver-
sus tamoxifen monotherapy in 4922 women.
Results
At a median follow-up of 71 months after randomization, disease-free survival was 
not significantly improved with either sequential treatment as compared with letro-
zole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99% confidence 
interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 
99% CI, 0.76 to 1.21). There were more early relapses among women who were as-
signed to tamoxifen followed by letrozole than among those who were assigned to 
letrozole alone. The updated analysis of monotherapy showed that there was a non-
significant difference in overall survival between women assigned to treatment with 
letrozole and those assigned to treatment with tamoxifen (hazard ratio for letro-
zole, 0.87; 95% CI, 0.75 to 1.02; P = 0.08). The rate of adverse events was as expected 
on the basis of previous reports of letrozole and tamoxifen therapy.
Conclusions
Among postmenopausal women with endocrine-responsive breast cancer, sequen-
tial treatment with letrozole and tamoxifen, as compared with letrozole monotherapy, 
did not improve disease-free survival. The difference in overall survival with letro-
zole monotherapy and tamoxifen monotherapy was not statistically significant. 
(ClinicalTrials.gov number, NCT00004205.)
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For decades, the standard adjuvant endocrine therapy for postmenopausal wom-en with hormone-receptor–positive early 
breast cancer was tamoxifen, taken for 5 years, 
a treatment that improved disease-free survival 
and reduced the number of deaths from breast 
cancer.1 More recently, reports from the Breast 
International Group (BIG) 1-98 trial2,3 and the 
Arimidex, Tamoxifen, Alone or in Combina- 
tion trial (ATAC; ClinicalTrials.gov number, 
NCT00849030)4,5 showed that 5 years of adjuvant 
therapy with an aromatase inhibitor alone improved 
disease-free survival as compared with 5 years of 
tamoxifen therapy; other large studies showed that 
switching to an aromatase inhibitor after initial 
treatment with tamoxifen improved survival.6-12 
A meta-analysis13 of trials of initial and sequen-
tial strategies supported the recommendation in 
guidelines that an aromatase inhibitor should be 
included in adjuvant therapy for postmenopausal 
women with endocrine-responsive early breast 
cancer.14-16
In the BIG 1-98 study, we compared mono-
therapy with tamoxifen, monotherapy with an aro-
matase inhibitor, and two sequential treatments: 
tamoxifen followed by an aromatase inhibitor (for 
which models predicting contradictory outcomes 
have been published17,18) and an aromatase inhibi-
tor followed by tamoxifen. Initial results from the 
BIG 1-98 trial showed that the aromatase inhibi-
tor letrozole given alone, as compared with ta-
moxifen given alone, reduced the risk of recurrent 
disease, especially at distant sites.2 In this report, 
we present the results of the comparison of each 
sequential treatment with letrozole monotherapy. 
We also present a protocol-defined updated analy-
sis of the comparison between 5 years of mono-
therapy with tamoxifen and 5 years of monothera-
py with letrozole.
Me thods
Study Design
The trial design has been described previous-
ly.2,3,19 Briefly, the BIG 1-98 trial is a randomized, 
phase 3, double-blind trial involving postmeno-
pausal women with estrogen-receptor–positive or 
progesterone-receptor–positive early breast cancer. 
Initially, from March 1998 through March 2000, 
women were randomly assigned to receive only 
letrozole (Femara, Novartis), 2.5 mg daily, or only 
tamoxifen, 20 mg daily, for 5 years; however, from 
April 1999 through May 2003, women were ran-
domly assigned to one of four study treatments: 
only tamoxifen for 5 years, only letrozole for 
5 years, letrozole for 2 years followed by tamoxifen 
for 3 years, or tamoxifen for 2 years followed by 
letrozole for 3 years (Fig. 1).
The primary end point was disease-free surviv-
al, defined as the time from randomization to the 
first of any of the following events (hereinafter 
called primary-end-point events): recurrence of the 
disease at a local, regional, or distant site; a new 
invasive cancer in the contralateral breast; any sec-
ond (nonbreast) cancer; or death without a previ-
ous cancer event. Other end points included time 
to the recurrence of breast cancer (including inva-
sive contralateral breast cancer but not consider-
ing second [nonbreast] cancers and with censoring 
of deaths that were not associated with a previous 
cancer event); time to distant recurrence, defined 
as the time from randomization to the recurrence 
of breast cancer at a distant site; and overall sur-
vival.
The 2005 results,2 which showed the superior-
ity of letrozole over tamoxifen, led to the recom-
mendation by the data and safety monitoring 
committee of the International Breast Cancer 
Study Group (IBCSG), and a decision by the BIG 
1-98 steering committee, to inform women in the 
tamoxifen-monotherapy group of their treatment, 
thereby allowing informed decisions to be made 
about their future care. An amendment of the pro-
tocol in April 2005 allowed for the provision of 
letrozole to any patient assigned to tamoxifen 
monotherapy who was free of disease, was receiv-
ing tamoxifen, and wished to cross over to letro-
zole (selective crossover). With respect to the three 
groups whose treatment regimens included letro-
zole, the double-blind nature of the study remained 
in effect.
Study Procedures
Clinical assessments were performed at baseline, 
every 6 months for the first 5 years, and yearly 
thereafter. Six-month supplies of study drugs that 
were identical in appearance and packaging were 
dispensed at each semiannual study visit for 5 years. 
Hematologic and blood chemical measurements 
and bilateral mammographic studies were per-
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
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formed at baseline and were repeated as medically 
indicated. Adverse events, including a cerebrovas-
cular accident or transient ischemic attack, cardiac 
ischemic infarction, angina requiring percutane-
ous transluminal coronary angioplasty, angina 
requiring coronary-artery bypass grafting, any 
thromboembolic event, other cardiovascular events, 
hypercholesterolemia (usually assessed when the 
patient was not fasting), bone fracture, vaginal 
bleeding, nausea, vomiting, hot flashes, and night 
sweats, were listed on the case-report forms and 
graded according to the Common Toxicity Crite-
ria (version 2) of the National Cancer Institute at 
each study visit. Other adverse events were record-
ed in free-text format on the case-report forms. 
Serious adverse events were reported promptly, in 
accordance with regulatory requirements.
The IBCSG was responsible for the design and 
coordination of the study, the collection and man-
agement of the data, the medical review, the 
analysis of the data, and the reporting of the re-
sults. The members of the trial steering commit-
tee (see Section 1 in the Supplementary Appendix, 
available with the full text of this article at NEJM.
org) reviewed the manuscript and were respon-
sible for the decision to submit it for publication. 
The ethics committee and relevant health authori-
ties at each participating institution approved the 
study protocol. All women gave written informed 
consent. The data and safety monitoring commit-
tee received safety data semiannually throughout 
the trial and reviewed three predefined interim 
efficacy analyses and the final efficacy analysis. 
Novartis, the manufacturer of letrozole, distrib-
uted the study drugs and provided financial sup-
port but imposed no restrictions on the inves-
tigators with respect to trial data. The IBCSG 
Statistical Center had full access to the trial da-
tabase (which included all data related to the 
trial, except for study-treatment assignment) and 
to the study-treatment-assignment database, but 
the IBCSG Data Management Center had access 
to the trial database only. The manuscript was 
prepared by the members of the writing commit-
tee, who made the final decisions about the con-
tent. Members of the steering committee (in-
cluding a minority representation from Novartis) 
reviewed the article and suggested changes. The 
chair of the writing committee vouches for the 
accuracy and completeness of the data. The data 
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Figure 1. Design of the Trial.
The numbers shown are for the intention-to-treat population, which excludes 18 enrolled women who did not receive a study treatment 
and who withdrew consent for use of their data (47 other women who refused study treatment did not withdraw consent for the use of 
their data and are included). The sequential-therapy analyses include 6182 women randomly assigned to one of four treatment groups 
(four-group randomization option only). The updated monotherapy analyses include 4922 women randomly assigned to letrozole mono-
therapy or tamoxifen monotherapy as part of either the two-group or the four-group randomization option.
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were analyzed by statisticians at the IBCSG Sta-
tistical Center.
The final efficacy analysis of the sequential 
treatments was reviewed by the data and safety 
monitoring committee in October 2008 and re-
leased to the steering committee when a protocol-
defined number of primary-end-point events had 
occurred. At the same time, the planned 10-year 
efficacy update of the monotherapy treatments 
was performed.
Statistical Analysis
The evaluation of sequential treatments involved 
only the women who participated in the four-group 
randomization option. To ensure adequate power, 
statistical considerations were based on primary-
end-point events that occurred after the fifth 
6-month supply of study medication was dispensed 
— that is, after the agents were changed in the 
sequential treatments (approximately 2 years after 
randomization). The objective was to assess the 
superiority of switching endocrine agents as com-
pared with continuing the initial agent. For each 
of the two pairwise comparisons (tamoxifen fol-
lowed by letrozole vs. tamoxifen and letrozole fol-
lowed by tamoxifen vs. letrozole), we calculated 
that at least 331 primary-end-point events after 
the switch in treatment would be needed for the 
study to have 80% power to detect a 29% reduc-
tion in the risk of a primary-end-point event after 
the switch. (Section 2 in the Supplementary Ap-
pendix shows the results of the treatment com-
parisons evaluated after the time of the switch in 
treatment.)
In 2005, on the basis of emerging data from the 
BIG 1-98 trial and other trials, the data and safety 
monitoring committee recommended that the 
steering committee revise the statistical-analysis 
plan to include five additional pairwise treatment 
comparisons, with analyses starting from the time 
of randomization. An amendment activated in 
April 2005, before any evaluation of results for the 
sequential-treatment groups was performed, spec-
ifies the comparisons, which include the two that 
are most clinically relevant: comparisons of each 
sequential treatment with 5 years of letrozole 
monotherapy. These comparisons are the main 
focus of this report. Post hoc power calculations 
showed that if the true reduction in the risk of a 
primary-end-point event was at least 26.7%, there 
was an 80% chance that the 99% confidence in-
terval would exclude a hazard ratio of 1.00. (Sec-
tion 3 in the Supplementary Appendix shows the 
results of the other three pairwise treatment com-
parisons specified in the amendment of April 
2005.)
Analyses were performed according to the in-
tention-to-treat principle. Kaplan–Meier20 esti-
mates of the time-to-event end points were cal-
culated. A Cox proportional-hazards regression 
analysis21 (stratified according to chemotherapy 
use, on the basis of the randomization stratum 
[Fig. 1]) was used to estimate P values and haz-
ard ratios, with 99% confidence intervals to ac-
count for the five comparisons described in the 
amendment of April 2005. We used cumulative-
incidence estimates22 to control for competing 
risks. The significance of differences in the inci-
dence of adverse events among the four treatment 
groups was assessed with the use of Fisher’s exact 
test; these analyses were not adjusted for mul-
tiple comparisons.
The study protocol specified that an updated 
analysis of the comparison of letrozole mono-
therapy with tamoxifen monotherapy be performed 
10 years after the beginning of the trial. We there-
fore updated the previous analysis3 of the 4922 
women who were assigned to one of the two 
monotherapy groups either as part of the two-
group or as part of the four-group randomization 
option. For this analysis, the Cox models were 
stratified both according to chemotherapy use and 
according to randomization option, and 95% con-
fidence intervals were calculated. Among the 2459 
women assigned to tamoxifen monotherapy, 619 
(25.2%) selectively crossed over to letrozole before 
a primary-end-point event occurred, and follow-up 
after the crossover accounted for 7.2% of total 
patient-years of follow-up. Women who selectively 
crossed over were more likely to have node-posi-
tive disease than those who continued to receive 
tamoxifen (46.9% vs. 29.0%). Crossovers occurred 
between 3 and 5 years after the start of therapy, 
and the average duration of letrozole therapy after 
crossover was 18 months. In addition to intention-
to-treat analyses, exploratory analyses were per-
formed in which data were censored at the time 
of crossover.
R esult s
Analysis of Sequential Treatment
Clinical Characteristics
A total of 8028 women were enrolled in the BIG 
1-98 trial; 18 withdrew consent and did not re-
ceive treatment, leaving an intention-to-treat pop-
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
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ulation of 8010 (Fig. 1). The sequential-treatment 
analyses were performed on the basis of the 6182 
women in the intention-to-treat population who 
were randomly assigned to a treatment group as 
part of the four-group option. This cohort includ-
ed 3604 women (58.3%) with node-negative dis-
ease, 3480 (56.3%) in whom the primary tumor 
was less than 2 cm, 3782 (61.2%) who underwent 
breast-conserving surgery, and 4596 (74.3%) who 
received no adjuvant or neoadjuvant chemotherapy. 
The median age at randomization was 61 years 
(range, 38 to 89). Clinical characteristics were 
well balanced across the four treatment groups 
(data not shown). The median follow-up period 
for the sequential-treatment analyses was 71 
months. The database for this report was locked 
on July 2, 2008.
Efficacy
Figure 2 shows the hazard ratios, with 99% con-
fidence intervals, for the comparisons of each of 
the sequential treatments with letrozole mono-
therapy with respect to the study end points. 
Differences between the treatment groups were 
not significant. The Kaplan–Meier estimates of 
the percentage of patients who remained disease-
free at 5 years after randomization were 87.9% 
in the group that was assigned to letrozole alone, 
87.6% in the group that was assigned to letrozole 
followed by tamoxifen, and 86.2% in the group 
that was assigned to tamoxifen followed by letro-
zole. The estimated 5-year rate of disease-free sur-
vival for women in the tamoxifen-monotherapy 
group was 84.6% on the basis of the intention-to-
treat analysis in which 612 of the 1548 women in 
the tamoxifen-monotherapy group (39.5%) crossed 
over to letrozole. Section 3 of the Supplementary 
Appendix shows the Kaplan–Meier curves for dis-
ease-free survival in all four groups, the sites of 
first primary-end-point events, and the hazard ra-
tios for the five pairwise comparisons.
Figure 3 shows the cumulative incidence of the 
recurrence of breast cancer among women in each 
of the two sequential-regimen groups as compared 
with the letrozole-monotherapy group, with sec-
ond, nonbreast primary cancers and deaths with-
out a recurrence of breast cancer considered as 
competing events. The risk of a recurrence of 
breast cancer with tamoxifen followed by letro-
zole did not differ significantly from the risk with 
letrozole alone (Fig. 3A and 3C). There was no dif-
ference in the outcome between women who were 
assigned to letrozole alone and those who were 
assigned to letrozole followed by tamoxifen, re-
gardless of nodal status (Fig. 3B and 3D).
Safety
Section 4 in the Supplementary Appendix shows 
the adverse events that occurred among women 
who were randomly assigned to a treatment group 
as part of the four-group option, according to time 
(years 1 and 2, 3 through 5, and overall) and 
Common Toxicity Criteria grade (any grade and 
grade 3 to 5, on a scale of 1 to 5, with higher 
numbers indicating worse toxic effects). There was 
a higher incidence of thromboembolic events 
among women who were assigned to one of the 
regimens that included tamoxifen than among 
those who were assigned to letrozole monother-
apy (4.1 to 4.9% vs. 2.4%, P<0.001). There were 
similar rates of stroke and transient cerebral ische-
mic attack between women who were assigned 
to one of the regimens that included tamoxifen 
and those who were not (1.7 to 1.9% and 1.4%, 
respectively; P = 0.74). The incidence of cardiac 
events of any type or grade was similar between 
women who were assigned to one of the regimens 
that included letrozole and women who were as-
signed to tamoxifen monotherapy (6.1 to 7.0% and 
5.7%, respectively; P = 0.45). The incidence of hy-
percholesterolemia (predominantly mild) was lower 
among women who were assigned to tamoxifen 
monotherapy than among those who were assigned 
to one of the regimens that included letrozole 
(29.9% vs. 41.4 to 53.2%, P<0.001).
Vaginal bleeding was reported in 9.9% of the 
women who were assigned to tamoxifen mono-
therapy, 5.1% of those who were assigned to letro-
zole monotherapy, and 6.4 to 7.5% of those who 
were assigned to sequential therapy (P<0.001). Hot 
flashes and night sweats occurred in all groups 
but were more frequent among women who were 
assigned to one of the regimens that included 
tamoxifen than among women assigned to letro-
zole monotherapy (hot flashes: 41.7 to 44.0% of 
women vs. 37.7%, P = 0.003; night sweats: 17.8 to 
19.4% vs. 15.6%, P = 0.04). Arthralgia, myalgia, or 
both were more frequent among women assigned 
to one of the regimens that included letrozole than 
among women assigned to tamoxifen monother-
apy (31.9 to 34.7% of women vs. 30.1%, P = 0.05), 
and the excess incidence among women in the 
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sequential regimens was seen during the periods 
when the women were receiving letrozole (Sec-
tion 4 in the Supplementary Appendix).
The incidence of fractures was highest among 
women assigned to letrozole monotherapy and 
lowest among women assigned to tamoxifen 
monotherapy (P = 0.02). The incidence of fractures 
among women assigned to tamoxifen followed by 
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Figure 2. Results of Cox Proportional-Hazards Analyses of Disease-free Survival, Overall Survival, and Time to Distant Recurrence,  
with Tamoxifen Followed by Letrozole as Compared with Letroz le Monotherapy and with Letrozole Followed by Tamoxifen  
as Compared with Letrozole Monotherapy. 
The events related to the end points are as follows: for disease-free survival, recurrence of the disease at a local, regional, or distant site; 
a new invasive cancer in the contralateral breast; any second (nonbreast) cancer; or death without a previous cancer event; for overall 
survival, death; and for time to distant recurrence, recurrence of cancer at a distant site. The models were stratified according to chemo-
therapy use. The size of the boxes is inversely proportional to the standard error of the hazard ratio. As specified in the protocol, 99% 
confidence intervals are shown to account for multiple comparisons. stimates of the percentage of patients without an event at 5 years 
are Kaplan–Meier estimates. Results of tests for interactions between treatment and nodal status were not significant. Nx denotes 0 
positive axillary lymph nodes with 1 to 7 nodes examined.
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letrozole was similar to that among women as-
signed to letrozole alone (9.4% and 9.8%, respec-
tively), and the incidence of fractures in the group 
assigned to letrozole followed by tamoxifen was 
similar to that among women assigned to tamox-
ifen alone (7.5% and 7.3%, respectively). Among 
the four groups, there was a similar number of 
deaths without a recurrence of breast cancer and 
of second (nonbreast) primary cancers, except for 
endometrial cancers, of which there were 13 cases 
in the group assigned to tamoxifen monotherapy, 
2 cases in the group assigned to letrozole mono-
therapy, and 4 cases in each sequential group 
(P = 0.01).
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Figure 3. Cumulative Incidence of the Recurrence of Breast Cancer. 
Results are shown for letrozole monotherapy as compared with tamoxifen followed by letrozole (Panels A and C) 
and for letrozole monotherapy as compared with letrozole followed by tamoxifen (Panels B and D). Both overall re-
sults (Panels A and B) and results according to nodal status (Panels C and D) are shown. The results are from a 
competing-risk analysis in which second, nonbreast cancers and deaths without a previous cancer event were con-
sidered as competing risks. The numbers of women with a first recurrence of breast cancer were as follows for the 
group assigned to letrozole monotherapy, the group assigned to tamoxifen followed by letrozole, and the group as-
signed to letrozole followed by tamoxifen, respectively: local recurrence, 12, 14, and 17 women; cancer in the con-
tralateral breast, 18, 19, and 16; regional recurrence, 7, 3, and 6; distant recurrence, 112, 130, and 105; and recur-
rence at an unknown site, 0, 3, and 0. Second, nonbreast cancers (64, 65, and 59 in the three groups, respectively) 
and deaths without a previous cancer event (35, 25, and 33, respectively) were also recorded as first primary-end-
point events.
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Updated Analysis of Monotherapy
The median follow-up period for the analysis that 
included women assigned to letrozole or tamox-
ifen monotherapy in both randomization options 
was 76 months. In the updated intention-to-treat 
analyses comparing letrozole monotherapy with 
tamoxifen monotherapy, there were 509 primary-
end-point events in the letrozole group versus 565 
events in the tamoxifen group (P = 0.03). The time 
to distant recurrence also differed significantly in 
favor of letrozole (P = 0.05) (Fig. 4). The 5-year over-
all survival was 91.8% in the letrozole group and 
90.9% in the tamoxifen group (hazard ratio, 0.87; 
95% confidence interval, 0.75 to 1.02; P = 0.08) 
(Fig. 4). The censored analyses (Fig. 4) suggested 
that there was more benefit with letrozole for each 
end point, but these analyses were subject to bi-
ases, some of which may have favored letrozole. 
The difference in the incidence of adverse events 
between the monotherapy groups changed little 
from that previously reported3 (data not shown). 
Eighty-seven deaths without prior cancer events 
were recorded in each monotherapy group. Sec-
tion 5 in the Supplementary Appendix gives fur-
ther details on the types of first primary-end-point 
events and the selective crossover.
Discussion
The main purpose of the BIG 1-98 trial was to com-
pare an aromatase inhibitor (letrozole) with ta-
moxifen as adjuvant therapy in postmenopausal 
women with endocrine-responsive early breast can-
cer. We report here analyses of letrozole mono-
therapy as compared with sequential treatment 
with tamoxifen and letrozole; in addition, we in-
vestigated whether letrozole monotherapy prolongs 
overall survival as compared with tamoxifen mono-
therapy. The limitations of the study include the 
selective crossover to letrozole among women as-
signed to tamoxifen monotherapy and the inabil-
ity, after a median follow-up period of 6 years, to 
assess the influence of a potential carryover ef-
fect of letrozole on the results.
In the analyses of sequential treatments, nei-
ther tamoxifen followed by letrozole nor letrozole 
followed by tamoxifen showed superiority over 
letrozole alone. A previous analysis of the trial 
data23 showed that the frequency of relapses 
within 2 years after randomization was signifi-
cantly reduced with letrozole as compared with 
tamoxifen, especially among women with many 
involved lymph nodes, large tumors, or vascular 
invasion. A similar pattern was seen in the cur-
rent analysis of the sequential-treatment cohort. 
There was a nonsignificant increase in the risk of 
early relapse among women with node-positive 
disease who were assigned to tamoxifen followed 
by letrozole (Fig. 3C). Since the interactions be-
tween treatment group and nodal status were not 
significant, caution is required in the interpreta-
tion of these subgroup analyses.24
The present analysis shows that treatment with 
letrozole for 2 years followed by tamoxifen yield-
ed outcomes similar to those seen with letrozole 
monotherapy. It is possible that part of this ef-
fect is a carryover benefit of the initial letrozole 
therapy, similar to that observed after cessation 
of anastrozole in the ATAC study.4 The follow-up 
of the BIG 1-98 trial is ongoing; the follow-up data 
that are currently available (median, 6 years) indi-
cate that, after 2 years of adjuvant therapy with 
letrozole, a switch to tamoxifen to complete 5 years 
of therapy would be acceptable, if cessation of 
letrozole is required for any reason.
Previous analyses of the BIG 1-98 trial have 
shown that, as compared with tamoxifen alone, 
letrozole monotherapy significantly reduces the 
risk of recurrence of disease, especially at distant 
sites.2,3 The updated intention-to-treat analysis of 
monotherapy confirms these observations and 
shows a nonsignificant difference between letro-
zole monotherapy and tamoxifen monotherapy 
with respect to overall survival (P = 0.08). Our belief 
that this result underestimates the survival ben-
efit that would have accrued if there had been no 
crossover to letrozole is based on evidence from 
independent trials that have shown a survival ben-
efit from switching to an aromatase inhibitor after 
initial treatment with tamoxifen.11,13 The censored 
analysis of overall survival, which suggests an even 
greater advantage of letrozole over tamoxifen than 
that seen in the intention-to-treat analysis (Fig. 4), 
may be an overestimate, particularly since women 
who had recurrent disease were not candidates for 
crossover (see Section 5 in the Supplementary Ap-
pendix). Thus, it is likely that the best estimate 
of the survival benefit with letrozole if there had 
been no selective crossover lies somewhere be-
tween these two extremes.
After 5 years of adjuvant endocrine therapy, re-
lapses continue to occur in women with endocrine-
responsive early breast cancer. Other trials have 
shown the value of extended therapy with an aro-
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matase inhibitor after 5 years of adjuvant therapy 
with tamoxifen.25,26 The ongoing Study of Letro-
zole Extension (SOLE; NCT00553410)27 is explor-
ing this concept in more detail and is adding an 
evaluation of intermittent letrozole as extended 
adjuvant therapy.28,29
The adverse-event profile and the number of 
deaths without a previous cancer event in the 
monotherapy and the sequential-therapy groups 
are reassuring. There were no unexpected life-
threatening adverse events in any group. The 
safety and efficacy results add to the information 
that supports the use of adjuvant endocrine ther-
apy with letrozole in postmenopausal women with 
endocrine-responsive early breast cancer and pro-
vide additional treatment options for such women.
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Figure 4 (facing page). Results of Cox Proportional-
Hazards Analyses of Disease-free Survival, Overall Sur-
vival, and Time to Distant Recurrence, with Letrozole 
Monotherapy as Compared with Tamoxifen Monothera-
py among Women Assigned to the Single-Agent Treat-
ment Groups. 
Results are shown for the total cohort and according to 
nodal status. Results of the intention-to-treat and cen-
sored analyses are presented. The events related to the 
end points are as follows: for disease-free survival, re-
currence of the disease at a local, regional, or distant 
site; a new invasive cancer in the contralateral breast; 
any second (nonbreast) cancer; or death without a pre-
vious cancer event; for overall survival, death; and for 
time to distant recurrence, recurrence of cancer at a 
distant site. The models were stratified according to 
study cohort (two-group or four-group randomization 
option) and chemotherapy use. The size of the boxes is 
inversely proportional to the standard error of the haz-
ard ratio. Estimates of the percentage of patients with-
out an event at 5 years are Kaplan–Meier estimates. 
The results of tests for interactions between treatment 
and nodal status were not significant. The intention-to-
treat analysis included all women and all follow-up 
time and events according to treatment assignment. 
The exploratory censored analysis was identical except 
that it excluded (i.e., censored) events and follow-up 
beyond the time of selective crossover among women 
randomly assigned to tamoxifen. Both analyses were 
subject to potential biases that may have influenced 
the estimated magnitude of the benefit with letrozole 
as compared with tamoxifen.
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